Researchers may have found a way to “cure” cat allergies?

Researchers aimed to boost immune tolerance to the major cat allergen Fel-d-1 by using high doses of CpG to increase the anti‐inflammatory activity of allergen-specific immunotherapy. They specifically chose high doses of CpG because it promotes Tregs.
February 22, 2021
Read

The antibody response to SARS-CoV-2 501Y.v2 variant and vaccine implications

Multiple studies from South Africa suggest that current SARS-CoV-2 vaccines based on the unmutated virus could have reduced efficacy in protecting against infection by the 501Y.V2 variant. We still need to determine if current vaccines protect against severe COVID-19.
February 19, 2021
Read

Do mutations in SARS-CoV-2 variants reduce the functional activity of mRNA-vaccine elicited Abs?

Wang et al. demonstrated that mutations found in new SARS-Cov-2 variants can reduce the neutralisation potency of mRNA-COVID-19 vaccinee and convalescent plasma against SARS-CoV-2 pseudo-typed viruses.
February 17, 2021
Read

IUIS/Immunopaedia-Frontiers Webinar on Immunoregulation and the tumor microenvironment

Prof. Ohashi presentation focused on PD-1 blockade, specifically why PD-1 based immunotherapies work for some cancers but not others. She began with an overview of PD-1...
February 12, 2021
Read

Are current putative COVID-19 vaccines effective against the B.1.351 variants?

Webinar by SA government featuring talks by Professors Shabir Madhi, Glenda Gray and Salim Abdool Karim suggests lower efficacy against the ChAdOx1/nCoV-19 vaccine (22%) but moderate to good efficacy of the Ad26 Vaccine (57%) against the B.1.351 variant.
February 9, 2021
Read

Phase 2a trial provides evidence for potential pancreatic cancer immunotherapy

Bockorny et al., demonstrated the utility of pembrolizumab, BL-8040 and chemotherapy against pancreatic cancer which resulted in better outcome (7/22 experiencing partial response) compared to immunotherapy without chemotherapy.
February 5, 2021
Read

COVID-19 is associated with increased MAIT cell activation and cytotoxicity

Flament et al., studied the immune cell landscape with respect to the MAIT cells, in a total of 208 patients at various stages of COVID-19. Their findings suggest a relationship between the outcome of SARS-CoV-2 infection and MAIT cell activation/cytotoxicity.
February 3, 2021
Read

Saliva viral load could be a potential correlate of severe COVID-19

Silva et al., found that saliva viral load was significantly higher in people with COVID-19 risk factors, correlated with increased disease severity, and was a stronger predictor of mortality over time compared to nasopharyngeal viral load.
February 1, 2021
Read

Mutations in SARS-Cov-2 B.1.351 variant reduces vaccine induced Ab neutralisation

Wu et al. demonstrate that mutations in the B1.1.7 did not affect the neutralisation capacity of mRNA-1273-vaccine induced antibodies, however mutations in the B.1.351 variant drastically reduced the neutralisation capacity of vaccine-induced antibodies.
January 27, 2021
Read

Immuno-metabolism and cognitive decline

Minhas et al. investigated whether an increase in PGE2 is associated with the development of age-associated maladaptive inflammation and cognitive decline. They focused their research on PGE2 because levels of PGE 2 are increased during neurodegenerative diseases and in monocytes from older (<65 yrs) compared to younger individuals (< 35 yrs).
January 25, 2021
Read